"Die FEK - Friedrich-Ebert-Krankenhaus Neumünster GmbH ist ein Akutkrankenhaus mit dem Auftrag der Schwerpunktversorgung. Es bietet Patienten eine umfassende medizinische und pflegerische Versorgung, die durch belegärztliche Leistungsangebote und medizinische Kooperationsverträge ergänzt und abgerundet wird. So verfügt das FEK über 646 Betten. In einem Einzugsgebiet, zu dem die kreisfreie Stadt Neumünster und weite Teile der angrenzenden Kreise gehören, behandeln unsere Teams jährlich rund 26.000 Patienten voll- und teilstationär sowie mehr als 55.000 Patienten ambulant. Als Akademisches Lehrkrankenhaus kooperiert das FEK mit den medizinischen Fakultäten des UKSH Kiel und der Universität Hamburg."

During the past decade, Friedrich Ebert Krankenhaus conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Friedrich Ebert Krankenhaus" #1 sponsor was "Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest" with 3 trials, followed by "Christian Buske" with 1 trials sponsored, "Dominik Paul Modest" with 1 trials sponsored, "EndoStim Inc." with 1 trials sponsored and "Ludwig-Maximilians - University of Munich" with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Friedrich Ebert Krankenhaus" #1 collaborator was "Roche Pharma AG" with 3 trials as a collaborator, "Amgen" with 1 trials as a collaborator, "BARMER GEK Germany" with 1 trials as a collaborator, "Bayer" with 1 trials as a collaborator and "Bristol-Myers Squibb" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Friedrich Ebert Krankenhaus" are "Cholangiocarcinoma" (2 trials), "Gallbladder Cancer" (2 trials), "Hepatocellular Cancer" (2 trials), "Oesophageal Cancer" (2 trials) and "Pancreatic Cancer" (2 trials). Many other conditions were trialed in "Friedrich Ebert Krankenhaus" in a lesser frequency.

Most popular intervention types in "Friedrich Ebert Krankenhaus" are "Drug" (3 trials), "Device" (1 trials), "Diagnostic Test" (1 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Bypass-Surgery" (1 trials), "Carfilzomib + Ibrutinib" (1 trials), "Catheter-based endovascular revascularization" (1 trials), "Copanlisib" (1 trials) and "Endarterectomy" (1 trials). Other intervention names were less common.

The vast majority of trials in "Friedrich Ebert Krankenhaus" are 9 trials for "All" genders.

Currently, there are NaN active trials in "Friedrich Ebert Krankenhaus". undefined are not yet recruiting, 6 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Friedrich Ebert Krankenhaus, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Friedrich Ebert Krankenhaus, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".